NCT05800366 2026-03-05A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell LymphomaDana-Farber Cancer InstitutePhase 2 Recruiting41 enrolled
NCT06867536 2025-03-18GLOHRT-01Huazhong University of Science and TechnologyPhase 2 Not yet recruiting40 enrolled